Matinas BioPharma announced that on March 21, the company received written notification from the NYSE American stating that the company has regained compliance with the NYSE American’s continued listing standards. Specifically, the company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in Section 1003(f)(v) of the NYSE American Company Guide due to shares of its common stock demonstrating sustained price improvement. In the notification, the NYSE American informed the company that the below compliance indicator will no longer be disseminated at the opening of trading on March 22, and the company will be removed from the NYSE American noncompliant issuers list on the NYSE American’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTNB:
- Matinas BioPharma’s MAT2203 Shows Renal Improvement and Infection Recovery
- Matinas BioPharma provides update from Compassionate/EUA Program with MAT2203
- Matinas BioPharma Advances MAT2203 in Phase 3 Global Trial
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- Matinas BioPharma reaches agreement with FDA for Phase 3 trial of MAT2203
